HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jan Marini Explores Anti-Aging Hair-Care Frontier With Revamped Conditioner

This article was originally published in The Rose Sheet

Executive Summary

Jan Marini Skin Research believes it is at the forefront of an anti-aging hair-care movement with its overhauled revitalizing conditioner, now branded as Marini Hair

You may also be interested in...



Rodan + Fields Prostaglandin Lash Boost Suit Appears Headed For Settlement

The San Francisco-based multi-level beauty marketer seems intent on putting an end to a multi-year, consolidated putative class action in California federal court alleging it failed to disclose risks associated with the prostaglandin analog in its Lash Boost conditioning serum.

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.

FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims

An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel